Risklick
Risklick develops Protocol AI TM, an end-to-end AI-driven software solution that enables experts to rapidly design and develop high-quality clinical trial protocols and study plans. The platform leverages a comprehensive database of over 800,000 clinical trials linked to publications, regulatory approvals, and safety data to optimize study design and accelerate clinical development timelines. It integrates with electronic trial systems like EDC and eTMF to streamline protocol implementation and change management, reducing protocol development time by 50%, amendments by 20%, and implementation time by 40%. Risklick's business model is subscription-based, targeting pharmaceutical companies and clinical research organizations to improve precision and efficiency in clinical trial protocol development, thereby accelerating market access for new treatments.
Risklick
Risklick develops Protocol AI TM, an end-to-end AI-driven software solution that enables experts to rapidly design and develop high-quality clinical trial protocols and study plans. The platform leverages a comprehensive database of over 800,000 clinical trials linked to publications, regulatory approvals, and safety data to optimize study design and accelerate clinical development timelines. It integrates with electronic trial systems like EDC and eTMF to streamline protocol implementation and change management, reducing protocol development time by 50%, amendments by 20%, and implementation time by 40%. Risklick's business model is subscription-based, targeting pharmaceutical companies and clinical research organizations to improve precision and efficiency in clinical trial protocol development, thereby accelerating market access for new treatments.
TL;DR
Headquarters: Bern, Switzerland
Flagship product: Protocol AI — AI-driven clinical trial protocol design platform
Database size: Over 800,000 clinical trials
Founded: 2019
Funding: Seed round led by Debiopharm Innovation Fund (Apr 23, 2024)
Related Companies
| Company |
|---|
 |
 |
 |
 |
 |